Despite positive studies, popularity of chemoprevention drugs increasing slowly.
Sarah L
SL
Zielinski
D011125:Adenomatous Polyposis Coli / Q000517:prevention & control; D000726:Androgen Antagonists / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D016588:Anticarcinogenic Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000517:prevention & control; D000068579:Celecoxib; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D011307:Drug Prescriptions / Q000706:statistics & numerical data*; D005260:Female; D018120:Finasteride / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000517:prevention & control*; D011471:Prostatic Neoplasms / Q000517:prevention & control; D011720:Pyrazoles; D013449:Sulfonamides / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use; D014481:United States
D000726:Androgen Antagonists; D000894:Anti-Inflammatory Agents, Non-Steroidal; D016588:Anticarcinogenic Agents; D018931:Antineoplastic Agents, Hormonal; D011720:Pyrazoles; D013449:Sulfonamides; D013629:Tamoxifen; D018120:Finasteride; D000068579:Celecoxib